Aim —to evaluate the clinical efficiency of strontium-89 chloride in the treatment of pain syndrome in patients with prostatic cancer (PC) with metastases in the bones. 99 patients with PC metastases to the bones were examined. Analgesic and antitumor effects of strontium-89 chloride were evaluated. Analgesic effect was noted in 73% of patients with hormone-resistant PC and 92% of patients receiving hormone therapy and biphosphonates, in whom the drug effect did not depend on the extent of tumor involvement. No effect was observed mainly in the patients with lytic lesions. Strontium-89 chloride contributes to bone tissue repair.

Strontium-89 chloride is an effective analgesic for patients with PC metastases in the bones. It can be used in complex with other treatments, promoting bone repair in some cases.